Navigation Links
FDA Reverses Stance on Removal of Morphine Painkiller
Date:4/9/2009

Appeals from hospice experts mean an unapproved drug, one of 14 given recent warning, will remain on the market, agency says,,,,

THURSDAY, April 9 (HealthDay News) -- Bowing to the pleas of hospice experts, the U.S. Food and Drug Administration has backed off its intent to remove from the market an unapproved liquid morphine painkiller given to dying patients.

Dr. Douglas Throckmorton, deputy director of the FDA's Center for Drug Evaluation and Research, told the Associated Press Thursday that the morphine liquid will remain on the market until replaced by an approved version or some other equivalent therapy.

The reversal follows a March 31 FDA warning to nine companies to stop making 14 unapproved prescription narcotic painkillers.

The liquid morphine was one of those painkillers, and is highly concentrated. Throckmorton said health officials had thought that other, more diluted forms of morphine could replace the concentrated one.

But, he told AP, reaction from hospice experts and others "helped us understand" that some patients need the unapproved version.

Dr. Porter Storey, executive vice president of the American Academy of Hospice and Palliative Medicine, called the FDA action "a really important step in the right direction." He added that it showed "an amazing level of responsiveness we're not used to seeing in our government officials," according to AP.

Deborah Autor, director of the Office of Compliance at the FDA Center, told reporters during a March 31 teleconference that the unapproved products posed a risk for consumers. "These include respiratory depression and other serious adverse events, including death," she said.

The batch of warning letters sent at the time was part of an ongoing effort to remove unapproved medicines from the market. Roughly 2 percent of all prescriptions in the United States are filled with unapproved drugs, according to the FDA.

"The FDA wants to assure consumers who rely on these products for pain relief that they will still have access to FDA-approved narcotic drugs and there will be no shortage for consumers," Autor told reporters.

Starting in late March, the companies had 60 days to stop manufacturing these products and 90 days to stop distributing them, Autor added. "FDA expects all manufacturers and distributors of unapproved versions of these products to honor these deadlines and will not tolerate any manufacture or distribution after these deadlines," she said.

The companies getting warning letters were: Boehringer Ingelheim Roxane Inc., of Columbus, Ohio; Cody Laboratories Inc., Cody, Wyo.; Glenmark Pharmaceuticals Inc., Mahwah, N.J.; Lannett Co., Philadelphia; Lehigh Valley Technologies Inc., Allentown, Pa.; Mallinckrodt Inc. Pharmaceuticals Group, St. Louis; Physicians Total Care Inc., Tulsa, Okla.; Roxane Laboratories Inc., Columbus, Ohio; and Xanodyne Pharmaceuticals Inc., Newport, Ky.

Throckmorton said Thursday that the stop-order for the other painkillers was still in place.

More information

For more on unapproved drugs, visit the U.S. Food and Drug Administration.



SOURCES: Associated Press; March 31, 2009, teleconference with Deborah Autor, J.D., director, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Md.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Combination therapy reverses effects of portal hypertension in rats
2. Gene Tweak Reverses Aging in Mouse Skin Cells
3. Gene therapy trains immune system to destroy brain cancer cells and reverses behavioral deficits
4. Court of Appeals Reverses Lower Court Decision in Favor of TriMed, Inc. Patent Infringement Case
5. Drug therapy for PKU reverses heart damage
6. Scripps Research scientists find seizure drug reverses cellular effects
7. New vaccine approach prevents/reverses diabetes in lab study at Childrens Hospital of Pittsburgh
8. HiCy drug regimen reverses ms symptoms in selected patients
9. Compound Reverses Huntingtons Symptoms in Mice
10. By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies
11. Fat on chest and upper back increases risk of insulin resistance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Reverses Stance on Removal of Morphine Painkiller 
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... change in their patients. Research shows that the Goal Attainment Scale (GAS) captures ... overcome this challenge and learn more about the Goal Attainment Scale, Education Resources ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club at Ibis ... prestigious Distinguished Emerald Club of the World award, as determined by the annual ... the most respected trade publications serving private clubs. , “We’d like to congratulate ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | Ticket ... Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation , ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of ... in the state still face a lot of restrictions as to where they can ... for private, personal use” and that cannabis “may not be consumed openly or publicly.” ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Mylan N.V. (NASDAQ, TASE: MYL) today announced ... December 31, 2015. --> --> ... revenues of $9.45 billion, up 28% on a constant ... of $9.43 billion. Excluding the impact of the acquisition ... generics business (the "EPD Business"), full year adjusted total ...
(Date:2/10/2016)... 10, 2016 --> ... & Gas), and Spectroscopy Market by Industry (Oil & Gas, ... & Paper, Metal & Mining, and Others), And Geography ... global market is expected to grow to USD 3.9 ... between 2015 and 2020. Browse 82 market ...
(Date:2/10/2016)... CSI Specialty Group (CSI) expanded its specialty ... Specialty Pharmacy Podcast. A free, weekly show, the Specialty ... education, discussion and context amongst specialty pharmacy peers and ... --> The Specialty Pharmacy Podcast, hosted by industry ... Suzette DiMascio, CHE, CMCE, CPC, is available for streaming ...
Breaking Medicine Technology: